Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01672996 · ClinicalTrials.gov registry record · Phase 1
Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers
A Phase 1 study, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT01672996 is a Phase 1 study that has completed, run by GE Healthcare. The registered enrollment target is 66 participants.
The verdict
NCT01672996, a Phase 1 study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
To optimize both the Ioforminol concentration and dosage(s) for CECT of the abdomen. To evaluate the safety and tolerability of low concentration Ioforminol Injections. Study recruits healthy volunteers.
Interventions
- DRUG Ioforminol 160 mgI/mL
- DRUG Ioforminol 200 mgI/mL
- DRUG Iopamidol 300 mgI/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2012-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01672996
The ClinicalTrials.gov registry entry for NCT01672996 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ioforminol 160 mgI/mL is the first listed.
NCT01672996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01672996 about?
NCT01672996 is a clinical study titled "Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers". To optimize both the Ioforminol concentration and dosage(s) for CECT of the abdomen. To evaluate the safety and tolerability of low concentration Ioforminol Injections. Study recruits healthy volunteers.
What is the current status of trial NCT01672996?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2012-07. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01672996?
The interventions under investigation include: Ioforminol 160 mgI/mL (DRUG), Ioforminol 200 mgI/mL (DRUG), Iopamidol 300 mgI/mL (DRUG).
Who is sponsoring clinical trial NCT01672996?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.